Turn weeks of manual research into answers in minutes. Powered by AI agents, backed by experts.
The trusted companion for pharmaceutical Pricing & Market Access teams.
Bayer Gilead and Kite Chiesi Lundbeck Genmab Kyowa Kirin
...and many more
0% churn
Since launch
8 of top 20
Pharma companies use Cellbyte
97%
User satisfaction*
*Based on user satisfaction survey in July/August 2026
Two ways to work with Cellbyte
Platform
Your team, supercharged by AI.
Give every analyst the reach of a global access function. From the first comparator question to the final pricing analysis, your team works across markets in one shared workspace, built on our proprietary clinical, regulatory, HTA and pricing database.
Research in plain language
Every output traceable to source
Automate complex, recurring workflows
Services
Our experts, delivering for you.
Life sciences experts combine deep domain knowledge with applied AI to solve complex Pricing & Market Access questions. Comprehensive evidence reviews, expert analysis and clear recommendations - in a fraction of the time traditional research takes.
Expert-led from scoping to delivery
Decision-ready, fully sourced deliverables
Delivered in days, not months
Expert deliverable
Disease landscaping · NMOSD
Export
00 Background
01 Unmet need
02 Pathways
03 Comparators
04 Deep-dive
05 HTA
06 Pricing
07 Price dev.
References
Section 05
HTA outcomes across five markets
Four EMA-approved options coexist with off-label immunosuppression; label boundaries, comparative evidence and monitoring requirements govern access.8,9,33 Every claim links to its primary source.31
Market
Outcome
Access condition
Germany
Minor added benefit
AQP4-IgG+ label only
France
ASMR IV
Relapsing, ≥ 2 prior lines
+ more markets
Discover how Cellbyte transforms your outcomes
Case study · Lilly Deutschland · Oncology · 521 procedures
Assessing the impact of biomarker status on benefit ratings and evidence confirmation
Rating mix by biomarker status
Major
Consid.
Minor
Non-q.
None
Biomarker
n=237
No biomarker
n=284
2 weeks
8 weeks
−75%
Research time
Published at ISPOR Europe 2026
German HTA added-benefit outcomes for biomarker-based drug therapies in oncology
Cellbyte saved me so much time. I can quickly check the sources and the specific passage where the AI found certain information.
Case study · Top-20 pharma · Oncology
Assessing the impact of OS length on benefit rating and pricing outcomes
Benefit-rating mix by OS gain
None
Small
Mod.
Subst.
Large
OS gain →
Stronger G-BA rating
8 hours
3 weeks
−93%
Research time
Discover customer case studies →
What Pricing & Market Access teams use Cellbyte for
Comprehensive analog research
Opportunity assessment / disease landscaping
Competitive intelligence
HTA & pricing research
Price evolution & comparison
Comparator & endpoint assessment
Launch sequence analysis
Outcomes validation
Treatment cost calculation
Find every relevant precedent asset, including pricing, access, and launch history, in minutes instead of weeks.
Map the treatment landscape, unmet need, and access environment for any indication before you commit resources.
Monitor competitor approvals, submissions, price changes, and access moves the moment they happen.
Query HTA decisions and price points across every major market, with the source one click away.
Track how prices moved after launch and benchmark them across countries, indications, and competitors.
Know which comparators and endpoints HTA bodies accepted, and which they rejected, before you build your dossier.
See how comparable assets sequenced their launches and model your own order against reference pricing rules.
Link your internal evidence with external payer data and appraisal outcomes ahead of negotiations.
Access pre-calculated treatment costs per drug and market, then recalculate using custom assumptions.
Run these yourself on the platform
Have them delivered by our specialists
Pharma runs on trust. So do we.
GDPR
EU compliant
GDPR EU Compliant
ISO/IEC 27001:2022 certified
ISO/IEC 27001:2022 Certified
SOC 2
Type II
SOC 2 Type II
Audit in progress
Your next Pricing & Market Access question, answered in minutes
Experience Cellbyte on an indication you're actually working on.
